FierceBiotech Names Oncorus as a "Fierce 15" Biotech Company of 2016

The scoop: This startup is pinpointing next-gen oncolytic viruses, which could offer a less expensive, more efficacious immuno-oncology option than cellular therapy, such as autologous CAR-Ts in development. It’s going straight for the hardest-to-treat solid cancers, including a type of brain cancer, glioblastoma multiforme (GBM).

Read the article from FierceBiotech.

Source: http://www.fiercebiotech.com/special-report/oncorus